Pazopanib Effects on Bleeding in Hereditary Hemorrhagic Telangiectasia
Status:
Unknown status
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The investigators will study whether Pazopanib, taken daily for 6 months, will reduce the
severity of nose bleeds in patients with hereditary hemorrhagic telangiectasia. Patients will
either be provided drug or a placebo [sugar non-drug pill], and be tested for nose bleed
severity throughout the trial, including particularly nose bleed duration. Investigators will
also test for blood loss, as well as for safety.